Carnival of Biotechnology
This edition of the Carnival of Biotechnology features a number of posts on distressing industry trends, some enlightening patent discussion, […]
This edition of the Carnival of Biotechnology features a number of posts on distressing industry trends, some enlightening patent discussion, […]
Guest content from John Avellanet, managing director of Cerulean Associates: As professionals affiliated with the biotechnology industry, we often forget
Harvard’s Gary Pisano has recently published a book titled “Science Business: The Promise, the Reality, and the Future of Biotech“
Lots of interesting developments since the last edition: Pfizer’s high-profile drug failiure, a new law against violent extremists, good news
Intellectual Property and Lawsuits Culture Dish has a post on a DNA sequencing technique patent dispute — Enzo biochem claims
This edition of the Carnival of Biotechnology features some interesting commentary on issues ethics, how to dress for drug ads,
This edition of the Carnival of Biotechnology features commentary on regulatory problems and progress, international development, and failed commercialization strategies.
Welcome to this week’s edition of the Carnival of Biotechnology. Some pretty good stuff this week. More Vioxx news, the
This week’s edition of the Carnival of Biotechnology addresses a number of issues challenging the biotechnology industry today. Innovation About
The latest carnival of biotechnology has been posted at Patent Baristas. Check it out for a fresh outlook on issues
Get new actionable insights and updates from BiotechBlog